Imidazopyrazine Crystal Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing imidazopyrazine derivatives, as BTK inhibitors, lack detailed information on crystal forms, which can significantly affect physicochemical properties, biological activity, bioavailability, and stability, posing challenges in pharmaceutical manufacturing and efficacy.
Innovation Solution
Development of crystal forms I, II, and III of the imidazopyrazine derivative, characterized by specific X-ray powder diffraction patterns, and preparation methods involving solvents and temperatures, enhancing solubility, stability, and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the compound is used without defined crystal form information, then the preparation process is simpler, but the physicochemical properties, biological activity, and stability are unpredictable and suboptimal
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions (solvent type, temperature, pH, concentration) to obtain different crystal forms with distinct physicochemical properties. This resolves the contradiction by establishing reliable stability through controlled parameter optimization while maintaining manageable process complexity.
Solution Approach 2:
The patent utilizes phase transitions by inducing crystallization from solution to obtain well-defined crystal forms. This transforms the compound from an undefined state to specific crystal structures (Form I, Form II, etc.) with predictable stability and bioavailability, resolving the reliability-complexity contradiction through controlled phase change.
2Ease of operation
If multiple crystal forms are developed, then solubility and bioavailability are improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent segments the single compound into multiple distinct crystal forms (Form I, Form II, Form III, etc.), each with optimized solubility characteristics. This allows selection of the most suitable crystal form for specific manufacturing needs, improving ease of operation while managing manufacturing complexity through systematic classification.
Solution Approach 2:
The patent employs parameter changes in crystallization conditions to generate different crystal forms with varying solubility profiles. By optimizing parameters such as solvent selection, temperature, and cooling rate, the patent achieves improved solubility and bioavailability while maintaining manufacturability through established pharmaceutical crystallization techniques.
3Manufacturing precision
If crystal form information is not established, then development time is shorter, but drug efficacy and safety are compromised
Solution Approach 1:
The patent applies preliminary action by conducting comprehensive crystal form characterization and selection during the early development stage. This establishes quality control parameters and selects the optimal crystal form before manufacturing scale-up, ensuring manufacturing precision while minimizing development time through proactive rather than reactive optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms exhibit improved solubility, bioavailability, stability, and reduced hygroscopicity, leading to enhanced drug efficacy and safety, with reduced dosage requirements and minimized side effects.
Implementation Method 1
dissolving the compound of formula (I) in diphenyl ether at 240 °C to 260 °C, and cooling to give the crystal form I
Implementation Method 2
cooling to give the crystal form I
Implementation Method 3
placing the compound of formula (I) in a solvent, and performing a reflux reaction to give the crystal form II
Implementation Method 4
performing a reflux reaction to give the crystal form II of the compound of formula (I)
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention belongs to the technical field of medicine, and specifically relates to a crystal form of an imidazopyrazine derivative represented by formula (I), a preparation method therefor and a use thereof.